SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2191365

Cover Image

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2191365

Colorectal Cancer Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

PUBLISHED:
PAGES: 191 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4850
PDF & Excel (Multi User License)
USD 6050
PDF & Excel (Enterprise User License)
USD 8350

Add to Cart

The Colorectal Cancer Diagnostics Market reached USD 14.50 billion in 2025 and is projected to grow at an 8.0% CAGR from 2026 to 2035. The market is expected to cross USD 31.30 billion valuation by 2035. Established endoscopy and pathology services operate alongside expanding stool-based and blood-based screening. Non-invasive testing can improve access while preserving the need for procedural confirmation and tissue assessment after positive findings. Commercial demand consequently spans several linked steps in patient care, connecting preliminary screening with more detailed diagnostic and surveillance requirements.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$14.50 Billion
Forecast Value$31.30 Billion
CAGR8%

Disease burden, expanded screening eligibility, and AI-assisted detection drive growth. A larger at-risk population supports initial tests, staging, follow-up, and lesion assessment. Screening access has a stronger commercial effect where patients can move efficiently from preliminary findings to colonoscopy, biopsy, pathology, and molecular evaluation. Policy-supported eligibility increases reimbursed orders and referrals, rewarding suppliers with accessible sample collection and established primary-care and payer relationships. AI detection adds software and service opportunities within existing endoscopy suites. As adoption extends into community and ambulatory centers, decision support and workflow integration can generate continuing demand beyond the replacement cycle of core diagnostic hardware.

Across test type, blood-based liquid biopsy is projected to reach USD 3.10 billion by 2035. Scaling requires regulatory access to become routine ordering in primary care, supported by payer coverage and useful clinical performance for patients with precancerous lesions. The category introduces a non-invasive route into screening, but commercial development depends on its integration into established diagnostic pathways. Suppliers need accessible testing that clinicians can order and patients can use within supported care arrangements. This makes adoption a matter of clinical utility and coverage as well as assay availability. The segment's opportunity therefore rests on converting a developing technology into repeatable participation in everyday screening practice.

By end use, hospitals are projected to reach USD 15.65 billion by 2035. Endoscopy suites, oncology services, pathology laboratories, and complex patient pathways concentrate activity in these institutions. Their combination of diagnostic functions supports purchasing across testing modalities and equipment types. Hospitals can connect screening results with procedures and laboratory assessment, making them important to integrated care delivery. Their commercial role reflects more than the provision of an initial test because patients may need several diagnostic steps within a coordinated system. Suppliers serving hospital accounts consequently address both specialized functions and the workflow relationships between imaging, endoscopy, pathology, and cancer services.

The North America colorectal cancer diagnostics market is projected to reach USD 12.00 billion by 2035. Established colonoscopy infrastructure, extensive diagnostic capability, and policy-supported screening sustain demand. Non-invasive approaches add access routes alongside existing procedures, creating referrals rather than eliminating confirmation requirements. In the United States, payer participation and installed capacity for endoscopy, pathology, and molecular testing support the commercial base. Suppliers need to connect testing access with follow-up capacity as screening participation broadens. The regional opportunity therefore combines established procedural systems with newer modalities that can bring additional patients into diagnostic pathways and support continuing surveillance and clinical assessment.

Exact Sciences held over 16.8% market share in 2025. Its stool DNA screening franchise and commercial reach support its position in non-invasive testing. An agreement for exclusive U.S. rights to Freenome's blood-based colorectal cancer screening tests expands participation in a developing category. This approach connects an established screening business with another collection pathway, strengthening exposure to different patient and clinician preferences. The company's commercial position rests on making screening accessible through its franchise and distribution capabilities. Its broader participation in non-invasive approaches also aligns with a market where preliminary testing can increase the need for confirmatory procedures and connected diagnostic services.

Some of the major players in this market are Olympus Corporation, Boston Scientific, Siemens Healthineers, Roche Diagnostics, Abbott, Guardant Health, GE HealthCare, QIAGEN, Danaher, Thermo Fisher Scientific, Sysmex, H.U. Group, DiaCarta, New Day Diagnostics, Phase Scientific International, and Geneoscopy. Equipment, reagents, laboratory systems, molecular testing, and specialized assays create different supplier positions. Olympus connects endoscopy with consumables, service, and AI workflows, while specialists pursue decentralized access and biomarker differentiation. Competition spans complementary stages of care, with clinical validation, reimbursement, and reliable follow-up important to adoption of new testing approaches.

Product Code: 6924

Table of Contents

Chapter 1. Research Methodology

  • 1.1 Research approach
  • 1.2 Quality Commitments
    • 1.2.1 GMI AI policy & data integrity commitment
      • 1.2.1.1 Source consistency protocol
  • 1.3 Research Trail & Confidence Scoring
    • 1.3.1 Research Trail Components
    • 1.3.2 Scoring Components
  • 1.4 Data Collection
    • 1.4.1 Partial list of primary sources
  • 1.5 Data mining sources
    • 1.5.1 Paid sources
      • 1.5.1.1 Sources, by region
  • 1.6 Base estimates and calculations
    • 1.6.1 Base year calculation
  • 1.7 Forecast model
    • 1.7.1 Quantified market impact analysis
      • 1.7.1.1 Mathematical impact of growth parameters on forecast
  • 1.8 Research transparency addendum
    • 1.8.1 Source attribution framework
    • 1.8.2 Quality assurance metrics
    • 1.8.3 Our commitment to trust

Chapter 2. Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Test type trends
    • 2.2.2 End use trends
    • 2.2.3 Regional trends
  • 2.3 TAM analysis, 2027-2035
  • 2.4 CXO perspectives: strategic imperatives

Chapter 3. Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier Landscape
    • 3.1.2 Profit Margin
    • 3.1.3 Cost structure
    • 3.1.4 Value addition at each stage
    • 3.1.5 Factor affecting the value chain
    • 3.1.6 Disruptions
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence and prevalence of colorectal cancer
      • 3.2.1.2 Government initiatives and policies associated with cancer screening tests
      • 3.2.1.3 Technological advancements in the field of cancer diagnostics
      • 3.2.1.4 Growing awareness regarding early diagnosis
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of diagnostic tests and procedures
      • 3.2.2.2 Lack of reimbursement policies for diagnostic tests
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion and adoption of non-invasive and AI-driven diagnostic technologies
      • 3.2.3.2 Rapid market growth in emerging regions
  • 3.3 Growth potential analysis
  • 3.4 Pricing Analysis (Driven by Primary Research)
    • 3.4.1 Historical Price Trend Analysis
    • 3.4.2 Pricing Strategy by Player Type (Premium / Value / Cost-plus)
  • 3.5 Regulatory landscape
    • 3.5.1 North America
    • 3.5.2 Europe
    • 3.5.3 Asia-Pacific
    • 3.5.4 Latin America
    • 3.5.5 Middle East and Africa
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis
  • 3.8 Trade Data Analysis (Based on Paid Database)
    • 3.8.1 Import/Export Volume & Value Trends
    • 3.8.2 Key Trade Corridors & Tariff Impact
  • 3.9 Impact of AI & Generative AI on the Market (Driven by Primary Research)
    • 3.9.1 AI-Driven Disruption of Existing Business Models
    • 3.9.2 GenAI Use Cases & Adoption Roadmap by Segment
    • 3.9.3 Risks, Limitations & Regulatory Considerations
  • 3.10 Future market trends
  • 3.11 Reimbursement scenario
  • 3.12 Consumer behaviour analysis
  • 3.13 Technology landscape
  • 3.14 Gap analysis
  • 3.15 Patent analysis

Chapter 4. Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 By Region
      • 4.2.1.1 North America
      • 4.2.1.2 Europe
      • 4.2.1.3 Asia-Pacific
      • 4.2.1.4 Latin America
      • 4.2.1.5 Middle East and Africa
    • 4.2.2 Market Concentration Analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Key developments
    • 4.5.1 Mergers & acquisitions
    • 4.5.2 Partnerships & collaborations
    • 4.5.3 New product launches
    • 4.5.4 Expansion plans and funding
  • 4.6 Company tier benchmarking
    • 4.6.1 Tier classification criteria & qualifying thresholds
    • 4.6.2 Tier positioning matrix by revenue, geography & innovation

Chapter 5. Market Estimates and Forecast, By Test Type, 2022-2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Blood tests
  • 5.3 Stool tests
    • 5.3.1 Fecal occult blood test (FOBT)
    • 5.3.2 Fecal biomarker test
    • 5.3.3 CRC DNA screening test
  • 5.4 Imaging tests
    • 5.4.1 CT
    • 5.4.2 Ultrasound
    • 5.4.3 MRI
    • 5.4.4 PET
    • 5.4.5 Colonoscopy
    • 5.4.6 Other imaging tests
  • 5.5 Biopsy
  • 5.6 Other test types

Chapter 6. Market Estimates and Forecast, By End Use, 2022-2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 Hospitals
  • 6.3 Diagnostic imaging centers
  • 6.4 Cancer research centers
  • 6.5 Other end use

Chapter 7. Market Estimates and Forecast, By Region, 2022-2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
    • 7.3.6 Netherlands
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 South Korea
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Argentina
  • 7.6 Middle East and Africa
    • 7.6.1 South Africa
    • 7.6.2 Saudi Arabia
    • 7.6.3 UAE

Chapter 8. Company Profiles

  • 8.1 Abbott Laboratories
  • 8.2 Danaher Corporation
  • 8.3 DiaCarta
  • 8.4 Exact Sciences Corporation
  • 8.5 F. Hoffmann-La Roche
  • 8.6 GE HealthCare Technologies
  • 8.7 Geneoscopy
  • 8.8 Guardant Health
  • 8.9 H.U. Group Holdings
  • 8.10 New Day Diagnostics
  • 8.11 Olympus Corporation
  • 8.12 Phase Scientific International
  • 8.13 QIAGEN N.V.
  • 8.14 Siemens Healthineers
  • 8.15 Sysmex Corporation
  • 8.16 Thermo Fisher Scientific
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!